QOL Up With Pembrolizumab Versus Ipilimumab, HDI in Resected Melanoma – Consumer Health News | So Good News


MONDAY, Nov. 28, 2022 (HealthDay News) — In patients with high-risk melanoma, adjuvant pembrolizumab improves quality of life (QOL) compared with standard care with ipilimumab or interferon α 2b (HDI), according to a study published online Nov. 23 in JAMA Oncology.

Joseph M. Unger, Ph.D., from the Fred Hutchinson Cancer Center in Seattle, and colleagues compared QOL in patients with high-risk melanoma who were treated with adjuvant pembrolizumab or standard of care. 832 patients from the S1404 phase 3 clinical trial were included and assessed for QOL endpoints at the 3rd phase.

The researchers found that the modified Functional Assessment of Cancer Therapy (FACT) Biological Response Modifiers (FACT-BRM) test result index (TOI) at cycle 3 was 9.6 points higher for pembrolizumab versus ipilimumab/HDI, which exceeded the reported difference. . The difference in the arm exceeded 5 points in favor of pembrolizumab in mixed models through 7. The FACT-BRM TOI index favored the pembrolizumab arm compared to a subset of patients receiving ipilimumab or HDI (difference, 6.0 and 17.0 points, respectively) post -hoc analysis.

“Physicians should be encouraged to incorporate and discuss treatment-related QOL issues with patients in making shared decisions about the risks and benefits of adjuvant therapy in resected melanoma,” the authors wrote.

Several authors disclosed financial information to pharmaceutical companies, including Merck, which manufactures pembrolizumab and provided partial funding for this study.

Abstract/Full Text (registration or payment may be required)


Source link